Travere Therapeutics (TVTX) Cash from Investing Activities (2013 - 2026)

Travere Therapeutics' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at $21.5 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 47.81% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 77.18% YoY) and the FY2025 annual result came in at $27.9 million, down 71.92% from the prior year.
• Cash from Investing Activities was $21.5 million for Q1 2026 at Travere Therapeutics, up from -$104.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $133.3 million in Q3 2023 and bottomed at -$104.8 million in Q4 2025.
• A 5-year average of $10.1 million and a median of $10.1 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 597.98% — and 2023, when it surged 1222.73%.
• Travere Therapeutics' Cash from Investing Activities stood at -$36.7 million in 2022, then surged by 53.82% to -$17.0 million in 2023, then sank by 373.8% to -$80.3 million in 2024, then sank by 30.54% to -$104.8 million in 2025, then jumped by 120.55% to $21.5 million in 2026.
• Business Quant data shows TVTX's Cash from Investing Activities at $21.5 million in Q1 2026, -$104.8 million in Q4 2025, and $86.6 million in Q3 2025.